Neuronostics, a Bristol-based medical technology firm, has successfully secured £3 million in funding to advance its innovative BioEP platform. This patented digital biomarker system is designed to revolutionize the diagnosis and prognosis of epilepsy. The investment round was co-led by Empirical Ventures and The FSE Group, signaling strong confidence in the company's potential to address significant challenges in neurological care.
Addressing a Critical Diagnostic Gap
Currently, individuals with suspected epilepsy often face a prolonged and uncertain diagnostic journey, with wait times exceeding a year. Misdiagnosis rates can be as high as 30 percent, and routine electroencephalogram (EEG) tests are inconclusive in over 70 percent of cases. This diagnostic ambiguity leaves clinicians without objective guidance and patients in a state of prolonged distress, with nearly half not achieving seizure control a year after starting treatment.
The BioEP Solution
Neuronostics' BioEP platform directly confronts this challenge by analyzing background EEG activity through a sophisticated set of computational biomarkers. This technology provides objective clinical decision support, generating a detailed report in under five minutes from a standard EEG recording. The platform is UKCA-marked and ISO-13485 certified, having been validated across 15 NHS sites, demonstrating its reliability and readiness for broader clinical application.
Strategic Allocation of New Capital
The new £3 million investment will fuel three key strategic initiatives for the company's growth and market penetration. A significant portion of the funds is allocated for pursuing US regulatory clearance, including a planned FDA submission in 2026. The capital will also support wider adoption of BioEP within the NHS and further develop the platform for use in pharmaceutical trials to measure treatment responses.
Investor Confidence and Market Opportunity
The funding round saw participation from a robust syndicate of investors, including British Business Bank’s South West Investment Fund, Ascension Ventures, and Angel Investors Bristol. Dr. Johnathan Matlock of Empirical Ventures noted that neurology has long needed objective tools and that this investment will help build a sustainable commercial presence. Ralph Singleton of The FSE Group also praised the company's outstanding scientific credentials and its potential for global impact.
This equity investment was further bolstered by a £400,000 grant from Innovate UK's Investor Partnerships program. John Terry, co-founder of Neuronostics, stated that the quality of the investor group reflects the significant commercial opportunity built upon a strong scientific foundation. He emphasized that the regulatory path is clear and NHS adoption is growing, reinforcing the company's mission to reduce patient waiting times.
Paving the Way for Global Expansion
A crucial element of Neuronostics' growth strategy is its expansion into the United States, the world's largest healthcare market. The company has established a strategic partnership with Stratus, the largest provider of EEG services in the US, which will facilitate a scalable deployment of BioEP. Charlie Alvarez, CEO of Stratus, confirmed that their integration is in place and that the planned FDA submission is a meaningful milestone for US patients.
This substantial funding round marks a pivotal moment for Neuronostics, equipping it with the resources to accelerate its mission. By enhancing diagnostic accuracy and speed for epilepsy, the BioEP platform is poised to significantly improve patient outcomes and reduce healthcare system burdens. The investment validates the company's innovative approach and paves the way for its technology to become a new standard of care in the UK and internationally.